JP2002508767A5 - - Google Patents

Download PDF

Info

Publication number
JP2002508767A5
JP2002508767A5 JP1999505154A JP50515499A JP2002508767A5 JP 2002508767 A5 JP2002508767 A5 JP 2002508767A5 JP 1999505154 A JP1999505154 A JP 1999505154A JP 50515499 A JP50515499 A JP 50515499A JP 2002508767 A5 JP2002508767 A5 JP 2002508767A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1999505154A
Other languages
English (en)
Other versions
JP4686696B2 (ja
JP2002508767A (ja
Filing date
Publication date
Priority claimed from AUPO7550A external-priority patent/AUPO755097A0/en
Application filed filed Critical
Publication of JP2002508767A publication Critical patent/JP2002508767A/ja
Publication of JP2002508767A5 publication Critical patent/JP2002508767A5/ja
Application granted granted Critical
Publication of JP4686696B2 publication Critical patent/JP4686696B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

Figure 2002508767
Figure 2002508767
Figure 2002508767
Figure 2002508767
Figure 2002508767
Figure 2002508767
Figure 2002508767
Figure 2002508767
JP50515499A 1997-06-25 1998-06-25 Ｃ５ａ受容体およびＧタンパク質結合受容体の環状アゴニストおよびアンタゴニスト Expired - Fee Related JP4686696B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU7550 1997-06-25
AUPO7550 1997-06-25
AUPO7550A AUPO755097A0 (en) 1997-06-25 1997-06-25 Receptor agonist and antagonist
PCT/AU1998/000490 WO1999000406A1 (en) 1997-06-25 1998-06-25 CYCLIC AGONISTS AND ANTAGONISTS OF C5a RECEPTORS AND G PROTEIN-COUPLED RECEPTORS

Publications (3)

Publication Number Publication Date
JP2002508767A JP2002508767A (ja) 2002-03-19
JP2002508767A5 true JP2002508767A5 (ja) 2006-09-21
JP4686696B2 JP4686696B2 (ja) 2011-05-25

Family

ID=3801840

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50515499A Expired - Fee Related JP4686696B2 (ja) 1997-06-25 1998-06-25 Ｃ５ａ受容体およびＧタンパク質結合受容体の環状アゴニストおよびアンタゴニスト

Country Status (12)

Country Link
US (5) USRE41287E1 (ja)
EP (1) EP1017713B1 (ja)
JP (1) JP4686696B2 (ja)
AT (1) ATE377606T1 (ja)
AU (2) AUPO755097A0 (ja)
CY (1) CY1107133T1 (ja)
DE (1) DE69838678T2 (ja)
DK (1) DK1017713T3 (ja)
ES (1) ES2294816T3 (ja)
HK (1) HK1029595A1 (ja)
PT (1) PT1017713E (ja)
WO (1) WO1999000406A1 (ja)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO755097A0 (en) * 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
AUPQ339899A0 (en) 1999-10-13 1999-11-04 University Of Queensland, The Novel molecules
WO2002014265A1 (fr) 2000-08-10 2002-02-21 Mitsubishi Pharma Corporation Nouveaux derives d'uree substitues en position 3, et leur utilisation en medecine
KR100842791B1 (ko) 2000-09-14 2008-07-01 미쓰비시 타나베 파마 코퍼레이션 신규한 아미드 유도체 및 그의 의약적 용도
AUPR833401A0 (en) * 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
WO2003078457A1 (en) 2002-03-19 2003-09-25 Cincinnati Children's Hospital Medical Center MUTEINS OF THE C5a ANAPHYLATOXIN, NUCLEIC ACID MOLECULES ENCODING SUCH MUTEINS, AND PHARMACEUTICAL USES OF MUTEINS OF THE C5a ANAPHYLATOXIN
WO2003084524A1 (en) * 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
AUPS160602A0 (en) * 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
AU2002950657A0 (en) 2002-08-08 2002-09-12 Alchemia Limited Derivatives of monosaccharides for drug discovery
AU2003266858B2 (en) * 2002-10-11 2006-09-14 Vast Bioscience Pty Limited Classes of compounds that interact with GPCRs
AU2002951995A0 (en) 2002-10-11 2002-10-31 Alchemia Limited Classes of compounds that interact with gpcrs
US7410945B2 (en) * 2002-10-16 2008-08-12 The University Of Queensland Treatment of inflammatory bowel disease
AU2002952086A0 (en) * 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis
AU2002952129A0 (en) * 2002-10-17 2002-10-31 The University Of Queensland Treatment of hypersensitivity conditions
AU2003902354A0 (en) * 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
AU2003902586A0 (en) * 2003-05-26 2003-06-12 The University Of Queensland Treatment of burns
WO2005014849A2 (en) * 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
EP1498422A1 (de) * 2003-07-17 2005-01-19 Jerini AG C5a-Rezeptor-Antagonisten
EP1797428A1 (en) * 2004-10-04 2007-06-20 Alchemia Pty Ltd Selective inhibitors
EP1838725A1 (en) * 2005-01-17 2007-10-03 Jerini AG C5a receptor antagonists
US20090117171A1 (en) * 2005-03-11 2009-05-07 Cedric Francois Compositions and methods for treatment of macular degeneration and related conditions
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
US20070292421A1 (en) * 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
HUE026001T2 (en) 2007-02-05 2016-04-28 Apellis Pharmaceuticals Inc Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
WO2009015087A2 (en) * 2007-07-20 2009-01-29 Potentia Pharmaceuticals, Inc. Compositions and methods for treatment of trauma
WO2009121065A2 (en) * 2008-03-28 2009-10-01 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
RU2479069C2 (ru) * 2008-07-02 2013-04-10 Сэн-Гобен Перформанс Пластикс Корпорейшн Шенё Каркасное устройство и способ его изготовления
ES2940466T3 (es) 2008-11-10 2023-05-08 Alexion Pharma Inc Métodos y composiciones para tratar trastornos asociados al complemento
CA2825137A1 (en) * 2010-01-22 2011-07-28 University Of Louisville Research Foundation, Inc Methods of treating or preventing periodontitis and diseases associated with periodontitis
SG185383A1 (en) 2010-04-30 2012-12-28 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
CA2839677A1 (en) * 2010-06-29 2012-01-12 Board Of Regents Of The University Of Nebraska Analogs of c5a and methods of using same
EP2468295A1 (en) 2010-12-21 2012-06-27 Affiris AG Vaccines based on peptides of the complement protein C5a
JP6618682B2 (ja) 2011-06-22 2019-12-11 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 補体阻害剤による慢性障害の治療方法
US9289467B2 (en) 2011-08-10 2016-03-22 Case Western Reserve University Compositions and methods for treating bone conditions
US20150241429A1 (en) * 2012-09-11 2015-08-27 Hospital For Special Surgery Irhom2 inhibition for the treatment of complement mediated disorders
SI3660033T1 (sl) 2012-11-15 2021-09-30 Apellis Pharmaceuticals, Inc. Analogi kompstatina z dolgotrajnim delovanjem in sorodni sestavki in postopki
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
AU2014248252A1 (en) * 2013-04-02 2015-10-29 M. Reza Ghadiri Uses of cyclic peptides for treating and preventing atherosclerosis
EA034870B1 (ru) 2013-08-07 2020-03-31 Алексион Фармасьютикалз, Инк. Белковые биомаркеры атипичного гемолитического уремического синдрома
CA3001128A1 (en) 2015-10-07 2017-04-13 Apellis Pharmaceuticals, Inc. Use of long-acting compstatin analog for treating a complement-mediated eye disorder
JP2019532021A (ja) 2016-07-29 2019-11-07 ファイザー・インク Ｃ５ａ受容体アンタゴニストとしての環状ペプチド
US20200057046A1 (en) 2016-10-27 2020-02-20 Alexion Pharmaceuticals, Inc. Assay for c5b-9 deposition in complement-associated disorders
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
ES2893769T3 (es) 2017-04-03 2022-02-10 Inflarx Gmbh Tratamiento de enfermedades inflamatorias con inhibidores de la actividad de C5a
KR20190139931A (ko) 2017-04-07 2019-12-18 아펠리스 파마슈티컬스 인코포레이티드 투여 요법 및 관련 조성물 및 방법
KR20200020727A (ko) 2017-06-23 2020-02-26 인플라알엑스 게엠베하 C5a 활성의 억제제를 사용한 염증 질병의 치료
WO2021067526A1 (en) 2019-10-02 2021-04-08 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
IL296036A (en) 2020-03-27 2022-10-01 Inflarx Gmbh c5a inhibitors for the treatment of corona virus infection
WO2021231720A1 (en) 2020-05-15 2021-11-18 Alexion Pharmaceuticals, Inc. Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease
WO2023186054A1 (zh) * 2022-04-02 2023-10-05 舒泰神（北京）生物制药股份有限公司 特异性识别c5a的抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5386011A (en) * 1990-12-27 1995-01-31 Abbott Laboratories Hexapeptide anaphylatoxin-receptor ligands
BR9408265A (pt) * 1993-12-06 1996-12-10 Ciba Geigy Ag Antagonistas de receptor de c5a não tendo substancialmente nenhuma atividade de antagonista
US5807824A (en) 1993-12-06 1998-09-15 Ciba-Geigy Corporation C5A receptor antagonists having substantially no agonist activity
US5614370A (en) * 1994-03-18 1997-03-25 Merck & Co., Inc. Assay to identify human C5a antagonists and agonists
US5696230A (en) 1994-08-31 1997-12-09 The Board Of Regents Of The University Of Nebraska High-affinity response-selective C-terminal analogs of C5a anaphylatoxin
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
AUPR833401A0 (en) 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
AUPS160602A0 (en) * 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
AU2002952086A0 (en) * 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis

Similar Documents

Publication Publication Date Title
JP2000509912A5 (ja)
JP2000510751A5 (ja)
JP2000507042A5 (ja)
JP2000509942A5 (ja)
JP2000509637A5 (ja)
JP2000509635A5 (ja)
JP2000507433A5 (ja)
JP2000509587A5 (ja)
JP2000507369A5 (ja)
JP2000510793A5 (ja)
JP2000508866A5 (ja)
JP2000508022A5 (ja)
JP2000508841A5 (ja)
JP2000508680A5 (ja)
JP2000509804A5 (ja)
JP2000509853A5 (ja)
JP2000510969A5 (ja)
JP2000509755A5 (ja)
JP2000508836A5 (ja)
JP2000509818A5 (ja)
JP2000509520A5 (ja)
JP2000510247A5 (ja)
JP2000507434A5 (ja)
JP2000508880A5 (ja)
JP2000509754A5 (ja)